BioStock: Biosergen towards first-in-patient trial with antifungal therapy

During Q1, Biosergen took major steps towards its goal to address the hidden threat of fungal infections. Not only was the company able to secure the necessary funding for the upcoming clinical phase Ib trial with BSG005, it also received the approval from the local authorities in India to procceed with the study. BioStock reached out to CEO Tine Kold Olesen for a comment on the company’s progress.

Read the article at biostock.se:

Biosergen towards first-in-patient trial with antifungal therapy - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/